Plasma Protein Profiling of Breast Cancer Patients of North Indian Population: A Potential Approach to Early Detection

2013 ◽  
Vol 06 (05) ◽  
Author(s):  
Deepika Arora
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Cancer Patients ◽  
Plasma Protein ◽  
Indian Population ◽  
Protein Profiling ◽  
North Indian Population ◽  
Breast Cancer Patients ◽  
Potential Approach

scholarly journals Serum N-glycan profiles differ for various breast cancer subtypes

2021 ◽  
Author(s):  
Gerda C. M. Vreeker ◽  
Kiki M. H. Vangangelt ◽  
Marco R. Bladergroen ◽  
Simone Nicolardi ◽  
Wilma E. Mesker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Cancer Patients ◽  
High Resolution Mass Spectrometry ◽  
Case Control ◽  
Total Serum ◽  
Screening Methods ◽  
Breast Cancer Patients ◽  
Cancer Subtypes ◽  
Control Comparison

AbstractBreast cancer is the most prevalent cancer in women. Early detection of this disease improves survival and therefore population screenings, based on mammography, are performed. However, the sensitivity of this screening modality is not optimal and new screening methods, such as blood tests, are being explored. Most of the analyses that aim for early detection focus on proteins in the bloodstream. In this study, the biomarker potential of total serum N-glycosylation analysis was explored with regard to detection of breast cancer. In an age-matched case-control setup serum protein N-glycan profiles from 145 breast cancer patients were compared to those from 171 healthy individuals. N-glycans were enzymatically released, chemically derivatized to preserve linkage-specificity of sialic acids and characterized by high resolution mass spectrometry. Logistic regression analysis was used to evaluate associations of specific N-glycan structures as well as N-glycosylation traits with breast cancer. In a case-control comparison three associations were found, namely a lower level of a two triantennary glycans and a higher level of one tetraantennary glycan in cancer patients. Of note, various other N-glycomic signatures that had previously been reported were not replicated in the current cohort. It was further evaluated whether the lack of replication of breast cancer N-glycomic signatures could be partly explained by the heterogenous character of the disease since the studies performed so far were based on cohorts that included diverging subtypes in different numbers. It was found that serum N-glycan profiles differed for the various cancer subtypes that were analyzed in this study.

scholarly journals Self-perceived Risk of Breast Cancer and Screening Behaviors of First-degree Female Relatives of Breast Cancer Patients at the Uganda Cancer Institute, Uganda

2021 ◽  
Author(s):  
Provia Ainembabazi ◽  
Derrick Bary Abila ◽  
Grace Manyangwa ◽  
Godwin Anguzu ◽  
Innocent Mutyaba ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Early Detection ◽  
Cancer Patients ◽  
Breast Cancer Screening ◽  
Perceived Risk ◽  
Breast Cancer Patients ◽  
Perceived Risks ◽  
First Degree Relatives ◽  
Cancer Breast

Abstract Introduction In Uganda, Breast cancer is the most common cancer in females globally. The majority of the patients present with advanced-stage disease at diagnoses and experience high mortality. This underscores the importance of early detection approaches based on awareness of risk factors and self-perceived risks, and symptoms of the disease to promote adoption of risk reduction behaviors and prompt health-seeking respectively. This study assessed the self-perceived risk of breast cancer, and breast cancer screening behaviours among first-degree female relatives of breast cancer patients in Uganda.Methods This was a cross-sectional study employing quantitative approaches for data collection and analyses. First-degree female relatives of patients attending care at Uganda Cancer Institute were recruited consecutively in the study. A pre-tested coded questionnaire was used to collect data on self-perceived risks, breast cancer risks, and breast cancer screening behaviours. Data were collected between March to October 2019. A modified Poisson regression model was used to evaluate factors associated with self-perceived risk of breast cancer and breast cancer risk awareness.ResultsWe enrolled 296 first-degree female relatives from 197 female breast cancer patients. The median age (IQR) was 33 (26-43) years. A majority (60.1%, 178/296) of the participants had a low self-perceived risk of breast cancer. Breast self-examination (55.7%, 165/296) was the most practiced screening method followed by clinical breast examination (n= 64/296, 21.6%), ultrasound scan of the breast (7.8%, 23/296,), and mammogram (3.7%, 11/296). Women aged 35-44 years had a higher self-perceived risk of breast cancer (adjusted Incident Rate Ratio [aIRR]: 1.75, 95%CI: 1.10-2.80), compared to women aged 18-25 years. ConclusionFirst-degree relatives reported a low self-perceived risk of breast cancer. Breast cancer health education especially targeting younger women should emphasize the increased risk of breast cancer in first-degree relatives of patients with breast cancer. There is a need to increase awareness of breast cancer screening methods and their usefulness in the early detection of breast cancer among all women in Uganda.

Analysis of BRCA1 gene exon 2 mutation in breast cancer patients in a South Indian population

2018 ◽  
Vol 11 (10) ◽  
pp. 4592
Author(s):  
Andrea Mary Francis ◽  
R. Ramya ◽  
Nalini Ganesan ◽  
P. Kumarasamy ◽  
Solomon F. D Paul ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Indian Population ◽  
Brca1 Gene ◽  
South Indian Population ◽  
Breast Cancer Patients ◽  
Exon 2 ◽  
South Indian ◽  
Gene Exon

Identification and validation of plasma protein biomarker panels for breast cancer diagnosis by using multiple reaction monitoring-based mass spectrometry.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10621-10621
Author(s):  
Hyeong-Gon Moon ◽  
Un-Beom Kang ◽  
Wonshik Han ◽  
Seock-Ah Im ◽  
Dong-Young Noh
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Plasma Protein ◽  
Multiple Reaction Monitoring ◽  
Breast Cancer Diagnosis ◽  
Reaction Monitoring ◽  
Breast Cancer Patients ◽  
Healthy Women ◽  
Protein Signature

10621 Background: Multiple reaction monitoring-based mass spectrometry (MRM-MS) has the ability to perform a wide range of proteome analysis in a single experiment using a small volume of specimen. We aimed to develop a plasma protein signature for breast cancer diagnosis using the MRM-MS technology. Methods: Previously, we have identified lists of breast cancer-related proteins from various models of proteomic discovery including cancer plasma vs healthy plasma, cancer cell line secretome vs non-tumorigenic cell line secretome, cancer tissue vs normal tissue, and literature search. Based on these protein panels, total of 29 proteins were selected for further experiments. We verified and validated the protein signature in two independent cohorts of breast cancer patients and healthy women. Results: In the verification cohort of 80 breast cancer patients and 80 healthy women, MRM-MS showed significant differences in plasma concentration for 11 proteins. Among them, the difference was not significant for 4 proteins when the cases were limited to stage I and II patients. Based on p values and consistent expression level along the AJCC stages, we have created a plasma protein signature comprised of 3 plasma proteins. The 3 plasma protein signature effectively discriminated cancer and healthy cases with the AUC of 0.831 (sensitivity 78.7%, specificity 78.7%). The performance of the 3 plasma protein signature was validated in the cohort of 100 cancer patients and 100 healthy women. The accuracy of the 3 protein signature was still meaningful with the AUC of 0.746 and 0.797 for all stages and stage I or II patients, respectively. Conclusions: The 3 plasma protein signature for breast cancer diagnosis, developed by the MRM-MS technology, showed promising results in the present study.

The use of new diagnostic tests for the monitoring of new and existing therapies for breast cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22006-e22006
Author(s):  
Andre Rotmann
Keyword(s):  
Breast Cancer ◽  
Glucose Metabolism ◽  
Early Detection ◽  
Cancer Risk ◽  
Cancer Patients ◽  
New Technology ◽  
Breast Cancer Patients ◽  
New Therapies ◽  
Non Invasive ◽  
Clinical Observations

e22006^ Background: Impaired glucose metabolism and elevated blood glucose levels have been linked with increased cancer risk and cancer mortality. Furthermore a diet with a high glycemic load and carbohydrate intake is positively associated with an increased cancer risk in a subgroup of breast cancer patients. New therapies have been established addressing new targets controlling glucose metabolism. Upregulation of glucose metabolism in cancer can be in vivo visualized by the imaging technique FDG-PET. Recently it has been shown that the detection of the biomarker transketolase-like-1 (TKTL1) in macrophages allows the non-invasive detection of upregulated glucose metabolism in cancer patients. The epitope detection in macrophages (EDIM) has been established as a new technology for a non-invasive biomarker based detection and characterization of tumors as well as early detection of recurrence and/or metastasis. The biomarker Apo10 is highly specifically expressed in tumor cells irrespective of the tumor entity. Apo10 and TKTL1 offers the possibility to detect abnormal cell proliferation and up-regulated glucose metabolism, indicating neoplasias and the degree of malignancy. This new technology could be used to identify patients that will benefit from existing and new approved therapies. Recently the mTOR inhibitor everolimus has been approved for a subgroup of advanced breast cancer. Metformin, a drug addressing glucose metabolism, has been shown to reduce the incidence of invasive breast cancer in postmenopausal women. Methods: We use the EDIM-tests for early detection, monitoring and in aftercare. Additional we use the test to monitor new therapies. The results where compared to clinical observations and laboratory data. Results: Up to now we have tested more than 100 women with breast cancer for a period up to 4 years. Our results show a good concordance between the EDIM-tests and the clinical observations. Conclusions: Our data from patients with breast cancer are promising results worth to be further validated. The combination of the biomarkers Apo10 and TKTL1 with EDIM-technology could be a useful tool to identify and monitor cancer patients and the use of new therapies.

Sign in / Sign up

Export Citation Format

Share Document